Site Navigation
General Information
Category: biotechnology & health
BSA 98-16: Generation of Phosphorylated Immunological Reagents
BNL Reference Number: BSA 98-16
Patent Status: U.S. Patent Number 6,309,863 was issued on October 30, 2001
Summary
A comparison of phosphoserine and its mimetic F2Pab. Shown are chemical diagrams of phosphoserine and F2Pab and two views of space-filling (Corey Pauling Koltum) models of the acetylated and methylamidated derivatives after energy minimization. Acetylation of the amino groups, methylamidation, and protonation of the phosphates simplified energy minimization calculations and approximated the local peptide environment. Energy minimization was accomplished with the Discover in Insight II program (Molecular Simulations Inc., San Diego, CA).
Describes a method for generating antibodies which specifically react to polypeptides phosphorylated at a specific amino acid.
Description
Describes a method for generating antibodies which specifically react to polypeptides phosphorylated at a specific amino acid.
Benefits
Circumvents the problem of rapid dephosphorylation upon immunization with the phosphopeptide antigen, thereby increasing the titer of the phospho-specific antibodies being generated.
Applications and Industries
The method can be used to generate both monoclonal and polyclonal antibodies with high titer.
Journal Publication
Have Questions?
For more information about this technology, contact Christine Brakel, (631) 344-7134.
Tags: cancer, diagnostic
